On Maj 19th 2025, Terranet AB (publ) will release its Interim report for the first quarter 2025. On the same day at 10 a.m. CET, the company’s CEO Lars Lindell and CTO Pierre Ekwall will provide an update on the operations in a webcast. The event will be broadcast digitally and is open to the public. The presentation will be held in English. Via the webcast, there is an opportunity to ask written questions. Link to the webcast: https://terranet.events.inderes.com/q1-report-2025A recording of the presentatio ...

16 May 2025 | 12:05AM HKT Greater China Semis: Apr: IC import/ export value +11.1%/ +20.2% YoY Semiconductor total revenues: The Mar 2025 data was up 9% YoY, or 2.3% MoM (vs. +6.6% YoY in Feb 2025, 27% YoY in Mar 2024), implying the steady recovery from the 5.3% YoY growth in Jan 2025. China semiconductor total revenue YoY growth continued and revenue was up to US$15.4bn in Mar 2025 (vs. US$14.1bn in Mar 2024). DOI for the electronics industry was 53 days in Mar 2025, around the level of the historical aver ...

uh I would like to talk about uh infinia uh most of you have probably seen we've done a pretty great announcement uh we delivered a product in version 20 lots of people ask why is it 2.0% well if it's already in production you shouldn't call it 1.0% at the time with G and so we gave it a 2.0% given that it's also a pretty significant large deployment we saw 2.0% is probably a a better number to start with so what is infinia uh infinia is our great software defined Next Generation data intelligence platform ...

BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. Brekiya autoinjector provides patients with the potential for sustained* pain relief in a con ...

魁北克市，加拿大, May 15, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc.（以下简称“LeddarTech”，Nasdaq：LDTC）是一家人工智能驱动的软件公司，因其在高级驾驶辅助系统 (ADAS) 和自动驾驶 (AD) 领域的创新而享有盛誉。公司现欣然宣布推出全新一代仿真平台 LeddarSim™，旨在缩小虚拟测试与实际部署之间的差距。 LeddarSim 通过对驾驶场景（包括摄像头、雷达和激光雷达输入）进行突破性的多模态神经重建，成功弥合了真实环境与仿真之间的长期鸿沟，为 ADAS 和 AD 技术开发树立了新标杆。 该平台能够实时生成传感器级精度的真实驾驶场景渲染，逼真还原现实世界的复杂性与动态变化，打造出高保真环境，助力开发者在贴近实际的条件下训练、测试与验证感知模型。 预计将为汽车原始设备制造商和一级供应商带来以下益处： 加快产品上市时间：LeddarSim 支持 ADAS/AD 工程师在虚拟环境下对数百万个可配置场景进行重建和测试，从而显著缩短开发周期，并加快验证速度。降低成本，不降质量：LeddarSim 在不牺牲准确性的前提下提供经 ...

SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET. The confere ...

Summary of Chimera's Conference Call Company Overview - **Company**: Chimera - **Industry**: Biopharmaceuticals, specifically focused on clinical stage drug development Key Points and Arguments FDA Interactions - Chimera has ongoing interactions with the FDA and other agencies, with no material changes observed in recent months [5][9] Manufacturing Plans - Current manufacturing is global, with a commitment to source commercial materials in the U.S. when possible [6][7] - The CEO highlighted a lack of infrastructure in the U.S. to support the biopharma industry, indicating a need for investment in basic research and infrastructure [8][9] Upcoming Catalysts - Healthy volunteer data for KT621 is expected in June, with a focus on presenting comprehensive data rather than piecemeal [14][15] - The STAT6 program is highlighted as unique, with potential to replicate the effects of existing blockbuster drugs like dupilumab [15][16] Biomarker Strategy - The primary biomarker for the STAT6 program is the degradation of STAT6 itself, which allows for direct measurement of target engagement [19][21] - Comparison with dupilumab's effects on biomarkers like TARC is discussed, with caution against drawing direct conclusions due to different study designs [20][21] Phase Ib Study - A Phase Ib study for atopic dermatitis (AD) patients has already begun, with expectations for robust biomarker changes and clinical endpoints by Q4 [25][26][48][49] Safety Profile - Previous studies indicated a good safety profile for related compounds, with no specific concerns for STAT6 degradation noted [34][36] - The CEO mentioned a subclinical QT effect observed in earlier studies, but no expectation of similar issues for the current drug [39][40] Competitive Landscape - The only oral approved drug for AD is a JAK inhibitor, which has safety concerns. Chimera's STAT6 degrader is positioned as a Th2-specific treatment [40][41] - The CEO expressed confidence in the differentiation of their product based on its mechanism of action [41][42] Future Development Plans - Chimera plans to develop the STAT6 drug across multiple indications, similar to dupilumab, with a focus on aggressive development strategies [63][64] - The company has a strong cash position of $775 million, expected to last until the first half of 2028, covering multiple data readouts [68][69] Additional Important Information - The CEO emphasized the importance of achieving over 90% STAT6 degradation for robust efficacy in clinical studies [28][31] - The company is prepared with multiple molecules in its pipeline, ensuring flexibility in case of underperformance in current studies [62][63] This summary encapsulates the key insights from Chimera's conference call, highlighting the company's strategic direction, upcoming milestones, and competitive positioning within the biopharmaceutical industry.

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences. Da ...

QUEBEC CITY, Canada, May 14, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an AI-powered software company recognized for its innovation in advanced driver assistance systems (ADAS) and autonomous driving (AD), is pleased to announce the launch of LeddarSim™, a next-generation simulation platform purposely built to reduce the gap between virtual testing and real-world deployment. LeddarSim redefines the standards of ADAS and AD development by closing the long-standing simu ...

Financial Data and Key Metrics Changes - The company reported a net loss of $22 million in the quarter compared to a net income of $6.2 million in the prior year, driven by higher general and administrative expenses and marketing costs [13] - Adjusted EBITDA was $4.1 million in the quarter, down from $22.2 million in the same quarter of the previous year [26] - Revenue grew 5.3% on a constant currency basis, but reported revenue was roughly flat year over year [12] Business Line Data and Key Metrics Changes - Paid content revenue grew 2.8% on a constant currency basis year over year, driven by strength in Japan, offset by declines in Korea and the rest of the world [17] - Advertising revenue increased by 13.6% on a constant currency basis, with strong performance in Korea and Japan, but a decline in the rest of the world [18] - IP Adaptation revenue saw a 20.7% increase year over year on a constant currency basis, with significant growth in Japan [19] Market Data and Key Metrics Changes - In Korea, revenue grew 3.6% year over year on a constant currency basis, primarily driven by advertising and IP adaptations [20] - Japan posted revenue growth of 9.4% on a constant currency basis, with all revenue streams contributing positively [22] - The rest of the world experienced a revenue decline of 4% year over year on a constant currency basis [24] Company Strategy and Development Direction - The company is focused on building a local creator ecosystem in Japan and expanding its cross-border strategy by taking Japanese content to other markets [6] - Investments are being made in the English language platform to enhance user experience and engagement [7][10] - The company aims to leverage its flywheel of creators, content, and users to generate profitable growth over the long term [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model despite potential market downturns, citing a low average revenue per paying user [10] - The company anticipates revenue growth in the range of 2.2% to 5.2% for the second quarter of 2025 [29] - Management is closely monitoring market health and believes in the long-term growth potential of newer markets [35] Other Important Information - The company faced challenges with a security upgrade affecting search engine indexing, which contributed to a decline in web MAU [14] - The gross profit for the quarter was $71.6 million, resulting in a gross margin of 22%, down from 25.2% in the prior year [25] - The company is making significant changes to its English language web comic app to improve user engagement [60] Q&A Session Summary Question: User growth initiatives and investment cadence - Management highlighted strong long-term growth signs in newer markets, particularly a 19% increase in English-speaking platform MAU [35] Question: Importance of local content in local markets - Management emphasized the significance of local creator IP and partnerships to enhance global reach and engagement [39] Question: MAU decline in Korea and future growth potential - Management noted that while Korea has high penetration, constant currency revenue growth of 3.6% indicates potential for future growth [46] Question: Update on advertising revenue in North America - Management stated that North America advertising is still in early stages, with a focus on building foundational products for future growth [49] Question: Impact of global franchises on monetization - Management clarified that global franchises have historically contributed positively to the core paid content margin structure [53] Question: Security update on Wattpad and user impact - Management confirmed that Wattpad's issues significantly impacted total MAU declines, but it is not a major contributor to paid content revenue [66] Question: Engagement levels of licensed IP in the U.S. - Management indicated that engagement levels depend on the specific IP, but there is potential for licensed IP to drive user engagement [85]